Table 2.
Powered endpoints across trials.
| Powered endpoint | Number of trials using the endpoint | Vaccine: Trials using the endpoint |
|---|---|---|
| HPV 16/18 incident infection | 1 | Cervarix: HPV-001/007/023 |
| HPV 16/18 12-month persistent infection | 1 | Cervarix: CVT |
| HPV 16/18 6-month persistent infection | 1 | Cervarix: Konno |
| HPV 6/11/16/18 CIN1+ | 1 | Gardasil: FUTURE I |
| HPV 16/18 CIN2+ | 5 | Cervarix: CVT, PATRICIA, Zhu Gardasil: FUTURE II, V501-041 |
| HPV 16/18 6-month persistent infection or CIN1+ | 2 | Cervarix: VIVIANE, Zhu |
| HPV 16/18 6-month persistent infection or external genital lesions or CIN1+ | 1 | Gardasil: FUTURE III |
| HPV 6/11/16/18 6-month persistent infection or external genital lesions or CIN1+ | 4 | Gardasil: V501-007, FUTURE III, V501-027, V501-041 |